Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
…, D Rea, L Legros, JM Cayuela, O Maarek, O Blanchet… - Blood, 2007 - ashpublications.org
In the present study, we address the issue of the discontinuation of imatinib mesylate (Gleevec)
in chronic myelogenous leukemia with undetectable residual disease for more than 2 …
in chronic myelogenous leukemia with undetectable residual disease for more than 2 …
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
…, A Renneville, P Cornillet, O Blanchet… - Blood, The Journal …, 2013 - ashpublications.org
Not all patients with core binding factor acute myeloid leukemia (CBF-AML) display a good
outcome. Modern risk factors include KIT and/or FLT3 gene mutations and minimal residual …
outcome. Modern risk factors include KIT and/or FLT3 gene mutations and minimal residual …
Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and …
…, L Stalnikiewicz, B Audhuy, O Blanchet… - Blood, 2004 - ashpublications.org
Various transplantation strategies have been designed to improve the poor prognosis of adult
(ages 15 to 60 years) acute lymphoblastic leukemia (ALL). The GOELAL02 trial evaluated …
(ages 15 to 60 years) acute lymphoblastic leukemia (ALL). The GOELAL02 trial evaluated …
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients
…, B Lioure, V Ugo, O Blanchet… - Blood, The Journal …, 2007 - ashpublications.org
The phosphoinositide 3-kinase (PI3K/Akt) pathway is activated in acute myelogenous
leukemia (AML) and is promising for targeted inhibition. Ninety-two patients with primary AML …
leukemia (AML) and is promising for targeted inhibition. Ninety-two patients with primary AML …
[HTML][HTML] Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF …
C Willekens, O Blanchet, A Renneville… - …, 2016 - ncbi.nlm.nih.gov
In t (8; 21)(q22; q22) acute myeloid leukemia, the prognostic value of early minimal residual
disease assessed with real-time quantitative polymerase chain reaction is the most …
disease assessed with real-time quantitative polymerase chain reaction is the most …
[HTML][HTML] Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not …
…, C Recher, A Pigneux, F Witz, N Vey, O Blanchet… - Blood, 2011 - Elsevier
Abstract 79 The prognosis of acute myeloblastic leukemia (AML) with intermediate-risk
cytogenetics is refined further by testing the mutational status of NPM1,FLT3 and CEBPa genes. …
cytogenetics is refined further by testing the mutational status of NPM1,FLT3 and CEBPa genes. …
[HTML][HTML] ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling
S Goossens, E Radaelli, O Blanchet, K Durinck… - Nature …, 2015 - nature.com
Early T-cell precursor leukaemia (ETP-ALL) is a high-risk subtype of human leukaemia that
is poorly understood at the molecular level. Here we report translocations targeting the zinc …
is poorly understood at the molecular level. Here we report translocations targeting the zinc …
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation
…, JM Chrétien, Y Delneste, N Ifrah, O Blanchet… - Blood …, 2020 - ashpublications.org
Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia
(ET) are the 2 entities associated with the most chronic disease course. Leukemic …
(ET) are the 2 entities associated with the most chronic disease course. Leukemic …
[HTML][HTML] Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
…, PM Roy, B Vielle, E Parot-Schinkel, O Blanchet… - Clinical Microbiology …, 2021 - Elsevier
Objectives To determine whether hydroxychloroquine decreases the risk of adverse outcome
in patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk of …
in patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk of …
Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks
…, Y Qu, V Gaidzik, O Blanchet… - Blood, The Journal …, 2011 - ashpublications.org
Cytogenetically normal acute myeloid leukemia (CN-AML) compose between 40% and 50%
of all adult acute myeloid leukemia (AML) cases. In this clinically diverse group, molecular …
of all adult acute myeloid leukemia (AML) cases. In this clinically diverse group, molecular …
